Mainz Biomed NV Investor Relations Material
Latest events
H2 2024
1 Apr, 2025
H1 2024
21 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mainz Biomed NV
Access all reports
Mainz Biomed NV is a Germany-based molecular genetics diagnostic company focused on early detection of cancer. The company develops and commercializes in-vitro diagnostic tests, including non-invasive screening tools for colorectal cancer and other conditions. It operates in European and global markets with a focus on regulated clinical validation. The company is headquartered in Mainz, Germany, and its shares are listed on the NASDAQ.
Key slides for Mainz Biomed NV
H2 2024
Mainz Biomed NV
H2 2024
Mainz Biomed NV
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
MYNZ
Country
🇺🇸 United States